COLUMBUS: encorafenib plus binimetinib versus vemurafenib or encorafenib in BRAF-mutant melanoma
The third BRAF-MEK combination, encorafenib plus binimetinib, delayed progression more than vemurafenib and produced the longest median survival of any targeted regimen in BRAF-mutant melanoma, with less fever than dabrafenib-trametinib.
Overview
Phase 3 trial of 577 patients with advanced BRAF V600-mutant melanoma randomised to encorafenib plus binimetinib, encorafenib alone or vemurafenib alone.
Median progression-free survival was 14.9 months with the combination against 7.3 months with vemurafenib (hazard ratio 0.54), and median overall survival 33.6 versus 16.9 months on later analysis; the combination had a distinct toxicity profile with less pyrexia and photosensitivity.
- Median progression-free survival 14.9 vs 7.3 months; hazard ratio 0.54.
- Median overall survival 33.6 vs 16.9 months.
Encorafenib-binimetinib is one of three standard BRAF-MEK doublets for advanced melanoma and is often chosen for its tolerability.
- Open-label; vemurafenib monotherapy is a dated comparator.
Similar pages
not linked directly; found by shared links- TrialA Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Shares Binimetinib, Encorafenib, BRAF V600-mutant melanoma.
- TrialAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
Shares Binimetinib, Encorafenib, BRAF V600-mutant melanoma.
- Key paperBRIM-3: improved survival with vemurafenib in melanoma with BRAF V600E mutation
Shares Vemurafenib, BRAF V600-mutant melanoma.
- Key paperPHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer
Shares Binimetinib, Encorafenib.
- TrialPhase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung
Shares Binimetinib, Encorafenib.
- PersonPaolo A. Ascierto
Shares COLUMBUS, Encorafenib, BRAF V600-mutant melanoma.
- Key paperBEACON CRC: encorafenib and cetuximab with or without binimetinib in BRAF V600E-mutated colorectal cancer
Shares Binimetinib, Encorafenib.
- PathwayMelanoma (KEGG map)
Shares Binimetinib, Vemurafenib, Encorafenib, BRAF V600-mutant melanoma.